DC-PEACETECH-LAB
24.12.2021 11:02:08 CET | Business Wire | Press release
The International Peace Honors (IPH), created by PeaceTech Lab , an award-winning non-profit organization founded by the United States Institute of Peace , will recognize Forest Whitaker, Ajay Banga, Juanes, Tokata Iron Eyes, Brandon Stanton, Dr. Lisa Su and Nicholas Donofrio for being global change-makers who have positively impacted the world through targeted activism. The virtual event airs Sunday, February 27th, 2022, at 8:00 pm EST. To register to watch visit: internationalpeacehonors.org .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211223005439/en/
“This year’s International Peace Honorees inspire us to greater hope and urgency, by showing what can happen when we leverage technology and media in their highest forms. From promoting peace and non-violence through music, to helping people improve their lives through the digital economy, protect the planet, and raise up a generation of new voices, their tireless work for the betterment of humanity is to be lauded. We are thrilled to recognize each of these outstanding social leaders,” said Sheldon Himelfarb , President & CEO, PeaceTech Lab.
Academy Award Winner, Forest Whitaker will receive the recognition for his everlasting commitment to empowering youth and promoting peace globally. Whitaker is the CEO/Founder of the Whitaker Peace & Development Initiative (WPDI), which provides educational tools and economic opportunities to young people in places touched by exclusion, violence and armed conflict.
Mastercard Executive Chairman, Ajay Banga will receive the honor for his outstanding contributions in bringing the digital economy to over 1 billion people, thus creating a sustainable economy through technology.
Renowned Singer-Songwriter and Social Advocate, Juanes will be honored for his dedication to youth empowerment and peace in his native Colombia through his Mi Sangre Foundation , a peace-building non-profit organization he co-founded alongside Catalina Cock Duque.
Youth Activist, Tokata Iron Eyes is set to be honored for her impassioned advocacy for Indigenous rights and the global climate movement. At age 18, she becomes the youngest person to receive the prestigious award.
Brandon Stanton , the creator of “Humans of New York” , will be celebrated for his dedication to fostering empathy and interconnectedness through powerful storytelling.
AMD ’s President and CEO, Dr. Lisa Su , will be recognized for revolutionizing high performance computing, donating supercomputing power for public good efforts focused on infectious disease research, and for inspiring people from all backgrounds to pursue careers in science and technology.
Lastly, former IBM EVP of Innovation and Technology Nicholas Donofrio , will receive the honor for his contributions to the international community of women and underrepresented youth in the fields of education, engineering, business and mathematics.
“The exceptionalism of our honorees reminds us that we’re all capable of rising to the challenges that negatively affect our world. I’m proud to extol their valuable social contributions and celebrate their vast achievements,” added MariaEsmeralda Paguaga , executive producer of the International Peace Honors .
The host, performers, and special guests will be announced in the upcoming weeks.
The International Peace Honors are made possible with the generosity of its sponsors and donors: Mastercard, BNY Mellon, The MITRE Corporation, Microsoft, Pitney Bowes, Liberty Mutual Insurance, Ernst & Young, Mercator XXI, KUDO, Wipro, and Alliance for Peacebuilding.
Follow @internationalpeacehonors for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211223005439/en/
Link:
Social Media:
https://www.facebook.com/peacetechlab/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom